These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 22377973

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol; 2009 Jul; 32(4):189-92. PubMed ID: 19620848
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
    Nyholm D, Lewander T, Gomes-Trolin C, Bäckström T, Panagiotidis G, Ehrnebo M, Nyström C, Aquilonius SM.
    Clin Neuropharmacol; 2012 Jul; 35(3):111-7. PubMed ID: 22549097
    [Abstract] [Full Text] [Related]

  • 9. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, Schlick P.
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P, Könen-Bergmann M, Schepers C, Haertter S.
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV, Hoff J, Mouradian MM, Chase TN.
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC.
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
    Modi NB, Mittur A, Dinh P, Rubens R, Gupta S.
    Clin Neuropharmacol; 2019 Sep; 42(5):149-156. PubMed ID: 31306216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.